Agios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020

Rhea-AI Summary

Agios Pharmaceuticals (NASDAQ:AGIO) announced its participation in the RBC Capital Markets Global Healthcare Virtual Conference on May 19, 2020, at 3:40 p.m. ET. A live webcast of the event will be available in the Investors section of Agios' website, with a replay accessible for two weeks post-event. The firm specializes in cellular metabolism to tackle cancer and rare genetic diseases, boasting a robust pipeline that includes two approved precision medicines and various investigational therapies. For further details, visit www.agios.com.

News Market Reaction – AGIO

+3.44%

+3.44% Session move

In the trading session that priced this news, AGIO gained 3.44%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020 at 3:40 p.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

About Agios
Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at www.agios.com.

Contacts

Investors:
Holly Manning, 617-844-6630
Director, Investor Relations
Holly.Manning@agios.com

Media:
Jessica Rennekamp, 857-209-3286
Associate Director, Corporate Communications
Jessica.Rennekamp@agios.com

FAQ

When is Agios Pharmaceuticals presenting at the RBC Capital Markets Global Healthcare Conference?

Agios Pharmaceuticals is scheduled to present on May 19, 2020, at 3:40 p.m. ET.

How can I watch Agios Pharmaceuticals' presentation at the virtual conference?

You can access the live webcast of Agios Pharmaceuticals' presentation in the Investors section of their website at www.agios.com.

Will the Agios Pharmaceuticals webcast be available after the live presentation?

Yes, a replay of the webcast will be available on the Agios website for at least two weeks following the presentation.

What areas does Agios Pharmaceuticals focus on in their research?

Agios Pharmaceuticals focuses on developing treatments for malignant hematology, solid tumors, and rare genetic diseases.

What products does Agios Pharmaceuticals currently have?

Agios Pharmaceuticals has two approved oncology precision medicines and multiple first-in-class investigational therapies.